FDA Approves Pluristem Therapeutics (PSTI)'s Commercial Scale Cell Manufacturing Process
3/6/2014 9:25:46 AM
HAIFA, Israel, March 6, 2014 (GLOBE NEWSWIRE) -- Pluristem Therapeutics, Inc. (Nasdaq:PSTI) (TASE:PLTR), a leading developer of placenta-based cell therapies, today announced that the United States Food and Drug Administration (FDA) has reviewed Pluristem's comparability studies of its PLacental eXpanded (PLX) cell products and granted approval for the Company to manufacture these products in its new commercial-scale cell manufacturing facility.
Help employers find you! Check out all the jobs and post your resume.
comments powered by